Profiteer's sentencing is a victory for FDA in fight against fake meds

07/15/2013 | FDA Voice blog

The FDA pays attention to reports of possible counterfeits and is collaborating with the private sector and other agencies to safeguard the country's drug supply, FDA Office of Criminal Investigations Director John Roth writes. The sentencing of Paul Bottomley last week for the wholesale marketing of misbranded and unapproved oncology drugs was a victory in the agency's push to guarantee access to high quality medicines, as well as ensure the safe distribution of treatments, he writes.

View Full Article in:

FDA Voice blog

Published in Brief: